L’impatto di baricitinib sui sintomi cutanei riportati dal paziente, sul prurito e sulla qualità di vita nei pazienti adulti con dermatite atopica moderata-severa e inadeguata risposta alle terapie topiche secondo i trial di fase 3 BREEZE-AD1 e BREEZE-AD2
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Messaggi chiave
- In due trial identici, indipendenti di fase 3, baricitinib in monoterapia si è dimostrato efficace nel migliorare la severità della patologia cutanea secondo le misurazioni riportate dai clinici e dai pazienti.
- I pazienti con DA moderata-severa hanno ottenuto un miglioramento clinicamente significativo del prurito già dalla 1a settimana rispetto al placebo.
- Baricitinib ha dimostrato una rapida comparsa dei miglioramenti delle lesioni cutanee e del prurito con un aumento clinicamente significativo della qualità di vita.
Presenting Author
Peter Lio, MD
Northwestern University Feinberg School of Medicine, Chicago, IL USA
Peter A Lio, MD, FAAD, serves as a Clinical Assistant Professor of Dermatology and Pediatrics at the Northwestern University Feinberg School of Medicine. He is also the Founding Director of the Chicago Integrative Eczema Center and a Founding Partner of Medical Dermatology Associates of Chicago. Dr Lio attended Harvard Medical School and completed the Harvard Combined Dermatology and Acupuncture program, serving as Chief Resident. With over 100 publications and 2 textbooks, he continues to focus on atopic dermatitis, eczema, and other inflammatory skin diseases. Dr Lio is a fellow of the American Academy of Dermatology, and member of the Society for Pediatric Dermatology, Chicago Dermatological Society, and Association of Professors of Dermatology. In 2016, he received the Feinberg School of Medicine Outstanding Teacher Award Teaching Pin.
Author disclosures
P. A. Lio has received grants as an investigator, and/or honoraria for lecturing, and/or consulting fees from: AbbVie, AOBiome, Arbonne, Burt's Bees, Dermavant, Dermira, Eli Lilly and Company, Exeltis, Franklin Bioscience/Altus Labs, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L'Oréal, Leo Pharma, Menlo Therapeutics, National Eczema Association, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB Pharma, Unilever, and Verrica.
This study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. Medical writing assistance was provided by Cassandra Haley, PhD, CMPP, of ProScribe – Envision Pharma Group, and was funded by Eli Lilly and Company
